SummitTX Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.29M Sell
35,791
-485
-1% -$120K 0.22% 110
2026
Q2
$8.74M Sell
36,276
-36,946
-50% -$8.09M 0.23% 110
2026
Q1
$13.8M Sell
73,222
-53,573
-42% -$9.36M 0.43% 37
2025
Q4
$21.6M Buy
126,795
+103,790
+451% +$15.9M 0.65% 22
2025
Q3
$3.03M Sell
23,005
-9,135
-28% -$1.1M 0.13% 182
2025
Q2
$3.41M Buy
32,140
+17,740
+123% +$1.93M 0.15% 168
2025
Q1
$1.79M Buy
+14,400
New +$1.88M 0.08% 271

Other funds holding JAZZ

SummitTX Capital's JAZZ Position: Q3 2026 in Review

SummitTX Capital reduced its Jazz Pharmaceuticals (JAZZ) stake by 1.3% in Q3 2026, selling an estimated $120K and leaving 35,791 shares worth $8.29M. The position accounts for 0.22% of the portfolio, ranked #110.

SummitTX Capital first reported a position in JAZZ in Q1 2025 and has held it in 7 quarters since. The position peaked at $21.6M in Q4 2025. 672 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • SummitTX Capital held 35,791 shares of Jazz Pharmaceuticals worth $8.29M as of Q3 2026.
  • SummitTX Capital sold 485 Jazz Pharmaceuticals shares in Q3 2026, an estimated $120K.
  • Jazz Pharmaceuticals made up 0.22% of SummitTX Capital's portfolio in Q3 2026, its #110 holding.
  • SummitTX Capital first reported a position in Jazz Pharmaceuticals in Q1 2025 and has held it in 7 quarters since.
  • SummitTX Capital's Jazz Pharmaceuticals position peaked at $21.6M in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on SummitTX Capital's 13F filing for Q3 2026, filed 16 Nov 2026.